GC2202 Study Site 109 — Greenville, North Carolina

GC2202 Study Site 109 is a clinical research site located in Greenville, North Carolina, United States 27843.

Crixeo Health Trust Score: 58/100 (POOR). This profile has not yet been claimed by the site owner.

GC2202 Study Site 109 has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia.

Sponsors: Grifols Therapeutics LLC.

Sponsor Feasibility Report

Trust Score: 58/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for GC2202 Study Site 109?

GC2202 Study Site 109 has a Crixeo Trust Score of 58/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has GC2202 Study Site 109 conducted?

GC2202 Study Site 109 has 1 clinical trials on record, with 1 currently active. Their work covers Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia.

Is GC2202 Study Site 109 accredited by Crixeo Health?

GC2202 Study Site 109 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about GC2202 Study Site 109?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.